BPC-157 with KPV
BPC-157 with KPV (gut and inflammation blend)
Written by Aaron CuhaReviewed Sep 2026
Also known as: BPC-157 KPV blend, Gut blend
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
This is two peptides in one vial, sold for gut trouble. The usual vial is 10 mg of each. BPC-157 came out of stomach juice research. KPV is a three amino acid piece of a hormone that calms inflammation. On paper it is the most sensible blend on the market. No one has ever tested it.
What people take it for
- Bloating, loose stools and reflux.
- So called leaky gut.
- Calming an inflamed bowel.
- Healing an injury at the same time.
What the trials actually showed
There is no trial of the pair. KPV has no human data at all. Not thin data. None. There is no registered study of it in people anywhere. What exists is two mouse gut studies, cell dishes, and a review that calls peptides like it future candidates. BPC-157 is barely better. The FDA counted five human studies with fewer than 110 people between them. Two were meeting abstracts. None ran past two weeks. None used a shot under the skin. Here is the part that gets missed. Both parts did their best work where the peptide touches gut tissue. The mouse KPV work was in the bowel. Much of the BPC-157 gut work went straight into the stomach. This product is sold to shoot under the skin. Nobody has compared the two routes in a person. Now the math. Mix 20 mg with 2 mL of water. Every unit mark carries 50 micrograms of each. A 5 unit draw is 250 micrograms of each. Some sellers use 5 mg and 5 mg, which halves all of that.
What people report
Reports, not trial results
The good
- Bloating and loose stools settling in the first two weeks.
- Less reflux. This is the most common single report.
- Joint and tendon pain easing as a bonus.
The bad
- Nothing at all is common.
- Symptoms come back when you stop. People read that as proof it worked. It is also just what an ongoing gut problem does.
- You cannot turn one part down or stop one part.
- You cannot tell which of the two did anything, because you took both.
Where these come from: Peptide and bowel disease forums, clinic write-ups and seller pages. Gut symptoms move around on their own and respond hard to what people expect. Most of these people changed their diet at the same time.
My bottom line
The idea is good and the evidence is not there. One half has never been given to a human being in a study. I would not pay peptide prices for that.
An opinion, not a finding. I am a coach, not a doctor.
Overview
Two peptides sold together for gut complaints, most commonly 10 mg of each in a 20 mg vial. The combination has never been studied. One half has five small human studies by routes nobody uses, the other half has no human data of any kind, and the vial is injected while the claim is about the gut.
This is the most coherent blend in the vendor catalogue on paper, which is why it is worth being careful about. BPC-157 came out of gastric juice research and its animal literature is largely gastrointestinal. KPV is the anti-inflammatory tail of alpha-MSH and its best animal work is mouse colitis. Two gut-facing peptides in one vial reads as a designed product rather than a bundle.
The arithmetic is simple because the split is usually even. Ten milligrams of each gives 20 mg of powder. Reconstitute with 2 mL and you have 10 mg/mL total, 5 mg/mL of each. One unit on a 100 unit insulin syringe is 50 micrograms of BPC-157 and 50 micrograms of KPV. A 5 unit draw is 250 micrograms of each. Some vendors sell 5 plus 5, which halves everything, so the milligram breakdown on the label decides the arithmetic and the name does not.
Now the part the product page does not say. KPV has no human data. Not thin human data, none: ClinicalTrials.gov returns no registered interventional study of KPV, and the published work is mouse colitis models, cell culture and nanoparticle delivery experiments. BPC-157's human file was counted by FDA staff in 2026 at five studies, fewer than 110 subjects, two of them meeting abstracts only, none running longer than two weeks and none using subcutaneous injection. So the injected version of the product has no human precedent for either component.
There is a second, quieter mismatch. Both components have their best evidence when they meet gut tissue directly. The KPV colitis work is intestinal. Much of the BPC-157 gut work is oral or intragastric. This blend is sold to be injected under the skin, which is a different exposure entirely, and no study has compared the routes in a person.
Mechanism of action
KPV blocks NF-kB and MAP kinase signalling in intestinal epithelial and immune cells, which is the mechanism behind its mouse colitis results. BPC-157 acts through angiogenic and cytoprotective pathways described on its own page and shows gastrointestinal protection in rodent models. Nothing published describes the two acting together, and there is no reason from the literature to expect the effects to add rather than overlap, since both converge on inflammatory signalling.
Human evidence
None for the pair. One component has no human data at all, which makes this blend unusual even in this category.
- The combination: no published study in any species and no registered trial.
- KPV: zero registered human studies. The evidence is two mouse colitis models, cell culture and a dermatology review that proposes melanocortin peptides as future candidates.
- BPC-157: five human studies counted by FDA, fewer than 110 subjects in total, two published only as meeting abstracts, none exceeding two weeks of dosing, none subcutaneous.
- A 2025 systematic review of BPC-157 in sports medicine included 36 studies, 35 preclinical, with the single clinical entry a retrospective series in which 7 of 12 knee patients reported relief beyond six months.
What this does not tell you: Neither component has been given to a human being by the route this product uses, for the indication this product is sold for, under controlled conditions. The blend therefore has no human precedent as a whole or in either half.
What it has been measured to do
Measured in animals or cells, not yet in people
Real results that answer a different question from a trial. Where a human trial is missing on a compound nobody can patent, the reason is usually that no sponsor would ever recover the cost of running one. The record on this one is set out below.
- Losing weight1 preclinical study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with BPC-157 with KPV, what they expect, and what goes wrong. The full account, including the negative reports, is below.
34 of the 36 indexed goals have no study of any kind behind BPC-157 with KPV
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about BPC-157 with KPV and one of these did not come from a study cited here.
Reading the research record
The mechanistic story here is better than most blends and that is exactly the trap. A coherent rationale is not evidence, and this category is full of coherent rationales that failed when someone finally ran the trial. Two gut-facing anti-inflammatory peptides converging on overlapping signalling may well add nothing to each other, and nobody has checked.
There is also a reporting problem specific to gut symptoms. They fluctuate, they respond to diet changes people make at the same time, and they respond strongly to expectation. Any uncontrolled report of a gut blend working is weaker evidence than the same report would be for a measurable outcome, which is why the forums on this product are unusually positive and unusually useless.
The evidence, charted
Fig. 1a · evidence scale
0people have taken this in any study cited here
0 participants · 0 human studies
What this page cites instead is 1 animal study and 3 reviews. None of it involved giving the compound to a person.
Counted from the citation list on this page. A figure is drawn here only when a human study is cited; an empty one is the finding, not a gap in the page.
Fig. 1b · evidence mix
None of the 4 citations here are human work.
- Animal · given to animals125%
- Review · summarises other work375%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2008 to 2026, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- A mixture. BPC-157 is about 1,419 Da and KPV about 342 Da, so the smaller peptide is a much larger share of the molecules than of the milligrams.
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend, and no pharmacokinetic study of the mixture exists. The components clear at different rates and no figure has ever been published for KPV in people.
No amino acid sequence is on file for BPC-157 with KPV, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
50%of a 20 mg BPC-157 with KPV vial is BPC-157
Label mass from a standard vial, not a dose, and not an assay. The ratio is fixed by the seller, so a draw that hits the amount you want of one component sets the amount of every other component with it. No study has tested this combination in any species.
Key studies & citations
- Animal2008
Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease
In two mouse colitis models KPV produced earlier recovery, greater body-weight regain, fewer inflammatory infiltrates and lower myeloperoxidase activity in colon tissue. Mice, KPV given alone, nothing here about a blend or about people.
Inflammatory Bowel Diseases - Review2019
Are melanocortin peptides future therapeutics for cutaneous wound healing?
A dermatology review describing KPV as a truncated alpha-MSH peptide that keeps the anti-inflammatory activity without the pigment-inducing activity, and proposing peptides of this class as future candidates for cutaneous wounds. The experimental approaches it surveys are in silico, in vitro, ex vivo and animal.
Experimental Dermatology - Review2026
FDA briefing document on BPC-157 for the July 2026 PCAC meeting
FDA staff counted five published human studies of BPC-157 totalling fewer than 110 subjects, two of them meeting abstracts only, none dosing longer than two weeks, and none giving the peptide by subcutaneous injection. Staff found no adequate human data and mislabelled products in the market.
FDA - Review2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
544 articles screened, 36 included, of which 35 were preclinical and one was clinical. That single clinical study was a retrospective series in which 7 of 12 patients reported relief beyond six months after intra-articular BPC-157 for unspecified chronic knee pain. The review puts the half-life at under 30 minutes.
HSS Journal
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Bloating and loose stools settling within the first two weeks.
- Less reflux, reported more often than any other single effect.
- Joint and tendon pain improving as a side effect, credited to the BPC-157.
- Nothing at all, which is common.
- Symptoms returning on stopping, which people read as proof it was working and which is equally consistent with the condition simply continuing.
Sources: Peptide and inflammatory bowel forums, clinic write-ups and vendor testimonial pages. Uncontrolled, usually alongside diet changes and other supplements. Reports, not evidence.
Frequently asked questions
Does KPV have any human studies?
No. ClinicalTrials.gov returns no registered interventional study of KPV, and there is no published human trial. Everything is mice, cells or review commentary.
How much of each am I injecting?
On the common 10 mg plus 10 mg vial reconstituted with 2 mL, each unit mark on an insulin syringe carries 50 micrograms of each peptide, so a 5 unit draw is 250 micrograms of each. A 5 plus 5 vial halves that.
Should I be taking this orally instead?
The gut evidence for both components was gathered where the peptide meets gut tissue: intragastric in the rodent BPC-157 work, intestinal in the KPV colitis models. This product is sold to inject. Nobody has compared the routes in a person, so the honest answer is that the route with the evidence behind it is not the route being sold.
Is this the same as KLOW without the copper and the TB-500?
Close. KLOW is these two plus TB-500 and a large copper peptide load. Stripping to two components removes the copper question and leaves the two ingredients whose claimed target is the same.
Can I lower one and keep the other?
Not from this vial. The ratio is fixed and the plunger moves both. If you want to find out which component is doing something, two single vials is the only version of this that can answer the question.